ConcertAI
ConcertAI's mission is to accelerate insights and improve patient outcomes through its leading real-world data, AI technologies, and scientific expertise. The company has established a comprehensive platform integrating deep, multi-modal oncology data with generative and agentic AI solutions, serving major life science clients and healthcare providers. Backed by significant investment from groups like SymphonyAI and Sixth Street, ConcertAI is positioned as a key enabler of precision medicine and efficient drug development.
Private Company
Total funding raised: $400M
AI Company Overview
ConcertAI's mission is to accelerate insights and improve patient outcomes through its leading real-world data, AI technologies, and scientific expertise. The company has established a comprehensive platform integrating deep, multi-modal oncology data with generative and agentic AI solutions, serving major life science clients and healthcare providers. Backed by significant investment from groups like SymphonyAI and Sixth Street, ConcertAI is positioned as a key enabler of precision medicine and efficient drug development.
Technology Platform
CARAai™, a generative and agentic AI platform, integrated with one of the industry's deepest and broadest multi-modal real-world oncology datasets, enabling solutions for real-world evidence, clinical trial acceleration, and commercial insights.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
ConcertAI faces competition from large RWD players like IQVIA and Flatiron Health (Roche), clinical trial tech firms like Medidata, and AI-driven drug development companies. Its differentiation lies in its integrated platform combining deep oncology-specific RWD, the generative CARAai™ engine, strategic partnerships (NVIDIA, ASCO), and a focus on autonomous 'agentic AI' solutions.